MSB News: William Blair Initiates Mesoblast Soon After Its Lead Product Goes Under FDA Review In Pediatric Ind - 10th Mar 2023, 5:02am

[annb0t]

William Blair has initiated coverage on Mesoblast Ltd (NASDAQ: MESO) with an Outperform rating and a price target of $8. Mesoblast's lead product, remestemcel-L, has shown transformative efficacy in pediatric steroid-refractory (SR) acute graft-versus-host disease (aGvHD), where no approved therapies exist for children under the age of 12. In a Phase 3 trial, 69% of pediatric SR-aGvHD patients treated with remestemcel-L were alive at day 180, and 51% were alive two years after treatment vs. 49% ...

>>> Read more: William Blair Initiates Mesoblast Soon After Its Lead Product Goes Under FDA Review In Pediatric Indication